Literature DB >> 6354027

Replication of lyophilized and cultured BCG in human macrophages.

A J Crowle, M H May.   

Abstract

If BCG must replicate well in vivo to immunize, presumably mainly in macrophages, the potency of BCG vaccines in human subjects might be measurable as the ability of the BCG to replicate in cultured human macrophages. We used this assumption to compare 6 different batches of lyophilized BCG with freshly cultured BCG and freshly cultured virulent Erdman tubercle bacilli, and to study how tubercle bacilli infect and multiply in human macrophages. The bacilli were readily phagocytized. They replicated in macrophages in proportion to how many were alive and how virulent they were, more the former than the latter among the lyophilized bacilli. The proportion of culturable bacilli in exponentially growing suspensions of BCG cultures was unexpectedly low. For suspensions of 5 of the 6 batches of lyophilized BCG, the great majority of bacilli were nonculturable. Suspensions made from the lyophilized BCG contained many large clumps of bacteria that resisted dispersion even by ultrasonic agitation. This clumpiness, presumably imparted to the bacilli during freeze-drying, caused the lyophilized BCG to infect macrophages more heavily than freshly cultured bacilli. In these experiments, native differences among macrophages from different subjects in capacity to phagocytize BCG and to inhibit its intracellular replication also were detected. These studies thus suggest that tests measuring responses of cultured human macrophages to infection with tubercle bacilli offer relatively simple, rapid, and human-being-related means for assessing several important aspects of human immunization with BCG.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6354027     DOI: 10.1164/arrd.1983.128.4.673

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  9 in total

1.  Relative permissiveness of macrophages from black and white people for virulent tubercle bacilli.

Authors:  A J Crowle; N Elkins
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

2.  Expression of virulence of Mycobacterium tuberculosis within human monocytes: virulence correlates with intracellular growth and induction of tumor necrosis factor alpha but not with evasion of lymphocyte-dependent monocyte effector functions.

Authors:  R F Silver; Q Li; J J Ellner
Journal:  Infect Immun       Date:  1998-03       Impact factor: 3.441

3.  Leucine auxotrophy restricts growth of Mycobacterium bovis BCG in macrophages.

Authors:  F C Bange; A M Brown; W R Jacobs
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

4.  Inhibition by 1,25(OH)2-vitamin D3 of the multiplication of virulent tubercle bacilli in cultured human macrophages.

Authors:  A J Crowle; E J Ross; M H May
Journal:  Infect Immun       Date:  1987-12       Impact factor: 3.441

5.  Activities of amikacin, roxithromycin, and azithromycin alone or in combination with tumor necrosis factor against Mycobacterium avium complex.

Authors:  L E Bermudez; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

6.  Diminished adherence and/or ingestion of virulent Mycobacterium tuberculosis by monocyte-derived macrophages from patients with tuberculosis.

Authors:  J Zabaleta; M Arias; J R Maya; L F García
Journal:  Clin Diagn Lab Immunol       Date:  1998-09

7.  Comparison of gamma interferon, tumor necrosis factor, and direct cell contact in activation of antimycobacterial defense in murine macrophages.

Authors:  J P Sypek; S Jacobson; A Vorys; D J Wyler
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

8.  Killing of Mycobacterium tuberculosis within human monocytes: activation by cytokines and calcitriol.

Authors:  M Denis
Journal:  Clin Exp Immunol       Date:  1991-05       Impact factor: 4.330

9.  Comparison of 15 laboratory and patient-derived strains of Mycobacterium avium for ability to infect and multiply in cultured human macrophages.

Authors:  A J Crowle; A Y Tsang; A E Vatter; M H May
Journal:  J Clin Microbiol       Date:  1986-11       Impact factor: 5.948

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.